Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying sorafenib and interferon alfa-2b to see how well
they work compared to sorafenib alone in treating patients with metastatic kidney cancer.
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib and
interferon alfa-2b may also block blood flow to the tumor. Giving sorafenib together with
interferon alfa-2b may kill more tumor cells.